|
|
| Santos,E.J.F.; Hortegal,E.V.; Serra,H.O.; Lages,J.S.; Salgado-Filho,N.; dos Santos,A.M.. |
| Anemia is an inevitable complication of hemodialysis, and the primary cause is erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis-stimulating agent (ESA). However, some patients remain anemic even after receiving this medication. This study aimed to investigate the factors associated with resistance to recombinant human erythropoietin therapy with epoetin alfa (αEPO). We performed a prospective, longitudinal study of hemodialysis patients receiving treatment with αEPO at our reference hospital from July 2015 to June 2016. Clinical data was collected, and the response to αEPO treatment was evaluated using the erythropoietin resistance index (ERI). The ERI was defined as the weekly weight-adjusted αEPO dose (U/kg per... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Epoetin alfa; Drug resistance; Renal insufficiency; Chronic disease; Renal dialysis. |
| Ano: 2018 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000700603 |
| |
